

Product Information

Size:

50ul

Reactivity:

Human

Source:

Rabbit

Isotype:

IgG

Applications:

ELISA, IHC

Recommended dilutions:

ELISA:1:2000-1:5000, IHC:1:50-1:200

Protein Background:

Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis.

Gene ID:

POMT1

Uniprot

Q9Y6A1

Synonyms:

protein-O-mannosyltransferase 1


Immunogen:

Synthetic peptide of human POMT1.


Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol

Product Images



The image on the left is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using PACO20262(POMT1 Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: x—200).



The image on the left is immunohistochemistry of paraffin-embedded Human brain tissue using PACO20262(POMT1 Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: x—200).